UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: precision medicine

Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?

The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.

Read More

Without challenge, there is no change – the move to precision medicine

I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.

Read More

Pricing Pressure, Payer Perspectives and Innovative Diagnostic Platforms

We spoke to Alex Bastian about how he got started in precision medicine, where he sees it going and how he intends to use real world evidence to unlock the potential around personalised approaches to drug development:

Read More

What’s been happening in precision medicine this month?

There has been some interesting news, discoveries and development to catch up on this month in the world of precision medicine. Take a look at the list below to find out more:

Read More

Connecting Cancer Biology to Clinical Oncology: Still a World to Win

Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.

Read More

The Challenges & Considerations of Reporting Somatic Variants in Cancer

Industrial and “omic” scale mutational profiling of solid tumours are possible as a result of massively parallel sequencing technology. However, these clinical genomic testing capabilities have also brought myriad new biological, technical and operational challenges not encountered in monogenic disorder testing. All of this impacts the interpretation and reporting of somatic variants. As a testament to the nascency of this field, the first published consensus guidelines for interpretation of variants in cancer was only released in early 2017.

Read More

Large-Scale Genetics Research: Q&A with Aris Baras

With genetic data making headlines, Aris Baras reflects on how genetic research can further advancements in medicine and delves into how his team’s work on large-scale approach is paving the way for new discoveries and enhanced patient care.

Read More

Immunotherapy for Malignant Mesothelioma

The current field of cancer research is seeing gains in almost every aspect of care, from the foundations of the disease to the development of successful treatment. With increased funding and attention to oncology care, immunotherapy and precision medicine are among the most promising patient-centred areas of current research and translational medicine.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive